Reply to: Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact

Vaccine. 2014 May 23;32(25):2943. doi: 10.1016/j.vaccine.2013.08.017. Epub 2013 Aug 17.

Authors

James Wassil¹, Jasper Huels², Vasant Narasimhan³

Affiliations

¹ Global Development, Novartis Vaccines and Diagnostics, Inc., 350 Massachusetts Avenue, Cambridge, MA, USA.
² Global Public Health and Market Access, Novartis Vaccines and Diagnostics A.G., Basel, Switzerland.
³ Global Development, Novartis Vaccines and Diagnostics, Inc., 350 Massachusetts Avenue, Cambridge, MA, USA. Electronic address: vas.narasimhan@novartis.com.

PMID: 23962533
DOI: 10.1016/j.vaccine.2013.08.017

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Male
Meningococcal Infections / economics*
Meningococcal Infections / prevention & control*
Meningococcal Vaccines / administration & dosage*
Meningococcal Vaccines / economics*
Neisseria meningitidis, Serogroup B / immunology*

Substances

Meningococcal Vaccines